Sotera Health (NASDAQ:SHC) Shares Sold by Phocas Financial Corp.

Phocas Financial Corp. reduced its stake in Sotera Health (NASDAQ:SHC) by 85.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,593 shares of the company’s stock after selling 248,619 shares during the period. Phocas Financial Corp.’s holdings in Sotera Health were worth $596,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Louisiana State Employees Retirement System lifted its holdings in shares of Sotera Health by 20.5% in the third quarter. Louisiana State Employees Retirement System now owns 42,400 shares of the company’s stock valued at $708,000 after buying an additional 7,200 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in Sotera Health in the 3rd quarter valued at about $850,000. State of Alaska Department of Revenue boosted its position in shares of Sotera Health by 31.7% during the 3rd quarter. State of Alaska Department of Revenue now owns 17,760 shares of the company’s stock valued at $296,000 after purchasing an additional 4,270 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in shares of Sotera Health in the 3rd quarter worth approximately $334,000. Finally, New York State Teachers Retirement System raised its holdings in shares of Sotera Health by 3.5% in the 3rd quarter. New York State Teachers Retirement System now owns 53,500 shares of the company’s stock worth $893,000 after purchasing an additional 1,800 shares in the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Sotera Health Trading Up 1.9 %

NASDAQ SHC opened at $13.73 on Wednesday. The firm’s 50 day moving average price is $13.48 and its two-hundred day moving average price is $14.54. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a twelve month low of $10.71 and a twelve month high of $17.44. The stock has a market cap of $3.89 billion, a price-to-earnings ratio of 54.92 and a beta of 1.91.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Royal Bank of Canada restated an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Thursday, November 21st. Citigroup raised their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Barclays cut their target price on Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, The Goldman Sachs Group started coverage on Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $16.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.